Teva Pharmaceutical and Ranbaxy Settle With N.Y. AG Over "Unlawful" Competition Agreement

The office of New York Attorney General Eric Schneiderman has reached a settlement with Ranbaxy Pharmaceuticals and Teva Pharmaceutical (NYSE: TEVA  ) that will require the two generic-pharmaceutical companies to terminate an agreement they reached in 2010, the AG announced in a press release today. The settlement addresses concerns that the agreement unlawfully restricted competition.

The agreement was initially made between Teva and Ranbaxy surrounding the production of a generic version of Lipitor, however the Attorney General's Office says the agreement "contained an unusual provision" in which the two companies agreed they would not compete against each other in certain drug categories.

The Attorney General's Office began its investigation in 2012, and concluded that the agreement was unlawful as it restricted competition, and sought to protect the two companies' market positions for a variety of different drugs and reduce the risk posed to the firms.

Ranbaxy and Teva neither admitted nor denied the AG's findings, according to the settlement.

As a result of the settlement reach today, the two companies will have to end their prior agreement and also ensure they do not enter into any similar agreements in the future. In addition, both Teva and Ranbaxy have been required to pay the state of New York $150,000. 

"Agreements between drug manufacturers to protect each other's market positions violate fundamental principles of antitrust law and can lead to higher drug prices," concluded Attorney General Schneiderman in a statement. "Drug companies should be aware that my office will intervene aggressively to root out collusion among industry players and ensure that New Yorkers receive access to critical drugs at fair value."


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2845467, ~/Articles/ArticleHandler.aspx, 9/4/2015 8:34:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Patrick Morris

After a few stints in banking and corporate finance, Patrick joined the Motley Fool as a writer covering the financial sector. He's scaled back his everyday writing a bit, but he's always happy to opine on the latest headline news surrounding Berkshire Hathaway, Warren Buffett and all things personal finance.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 4:01 PM
TEVA $64.12 Down +0.00 +0.00%
Teva Pharmaceutica… CAPS Rating: *****